You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》石藥集團(01093.HK)首季純利11.6億人幣升21.8%
阿思達克 05-27 12:01
石藥集團(01093.HK)公布截至今年3月底止首季業績,營業額61.25億元人民幣(下同),按年升11.5%。純利11.59億元,按年升21.8%;每股盈利18.59分。不派息。

期內,毛利為45.29億元,按年增長17.9%;經營溢利11.63億元,按年微升0.6%。

按業務劃分,首季成藥收入按年升18.3%至50.22億元;維生素C收入跌18.6%至4.26億元;抗生素收入跌40.1%至2.08億元;其它收入升24.3%至4.69億元。

集團首季研發費用為5.68億元,較去年同期增加23.2%。

集團表示,由於新型冠狀病毒疫情爆發期間全國各地採取封閉式管理,醫院門診量及住院率均受到影響,市場活動及藥品配送亦受到阻礙,以致集團成藥產品的銷售受到不同程度的影響。在疫情期間,集團一方面積極配合政府的各項防控措施,並全力生產阿比多爾等臨床急需產品。今年首季業績不可避免地受到疫情的拖累,銷售收入及核心利潤的增長均低於預期。集團又提到,未來三年預計將上市新產品50餘個,其中預計市場空間超過10億元的重磅品種將不少於15個,可強力支撐集團未來的高質量增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account